via University of Reading
An antioxidant drug reverses atherosclerosis and could be used to prevent heart attacks and strokes due to clots, according to research funded by the British Heart Foundation (BHF) and published today in JAHA: Journal of the American Heart Association.
Atherosclerosis is the build-up of fatty deposits in the arteries. When a type of fat called LDL cholesterol becomes oxidised and builds up to form plaques in the artery walls, inflammation and damage increase which can cause the plaques to rupture and cause blood to clot.
These clots can block vital arteries that allow blood to flow to the heart, causing a heart attack, or to the brain causing a stroke.
Previously, researchers at the University of Reading discovered that LDL cholesterol can be oxidised in acidic small ‘bags’ called lysosomes in immune cells within the artery wall.
Now, Professor David Leake and his team have found that the antioxidant drug, cysteamine, has the power to switch off, and even reverse, this damaging process.
Cysteamine works by accumulating in the lysosomes and stops the oxidation of LDL cholesterol. It is already known to be safe in humans where it’s used to treat a rare lysosomal disease called cystinosis.
When the researchers looked at mice with atherosclerosis, those treated with cysteamine had a 32 to 56 per cent reduction in the size of atherosclerotic plaques depending on the part of the aorta – the largest artery in the body – that was examined.
Cysteamine decreased the amount of oxidised fat by 73 per cent and increased the stability of the atherosclerotic areas. It decreased the proportion of inflammatory white blood cells by 55 per cent and increased the area made up of smooth muscle cells by 85 per cent, ultimately reducing the chance of plaques rupturing and causing a blood clot.
Antioxidant drugs that have previously produced promising results in mice have proven disappointing in clinical trials to treat cardiovascular disease, but the researchers hope that with these promising results, cysteamine will prove a successful treatment in humans.
Professor David Leake, Professor of Biomedical Sciences at the University of Reading who led the study said:
“The potential in this drug to protect against heart attacks and strokes and ultimately save lives superseded our expectations. We hoped it would cause plaques to grow at a slower pace, but we were amazed to find it reversed the process.
“Cysteamine would offer an entirely new way of treating atherosclerosis. We now want to look at the most efficient way to give this drug to patients, and hope that it can be taken to clinical trials in the next few years.”
Professor James Leiper, Associate Medical Director at the British Heart Foundation, which funded the research said:
“Heart attacks and strokes threaten the lives of people too often. In the UK, every 5 minutes someone is admitted to hospital with a heart attack, and the same is true of stroke. “The more ways we can find to treat the root cause of cardiovascular disease, the more lives and livelihoods that can be saved.
“If this antioxidant drug can show the same promising effects in humans, then it could offer a lifeline to thousands of people in the future.”
More from: University of Reading
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- 15 New Products for All of Your Mid-Summer Beauty Struggleson August 1, 2022 at 1:33 pm
Erin is a Brooklyn-based beauty editor and has been with InStyle since 2016. She's written for NYLON, Teen Vogue, Into The Gloss, FASHION Magazine, and more. She graduated with an Honors B.A. in ...
- Upcycling of waste ABS into 3D-printable material with enhanced propertieson July 31, 2022 at 9:00 pm
In an advancement toward circularity for commodity plastics, researchers at the Oak Ridge National Laboratory (ORNL; Oak Ridge, Tenn.; have developed a method for upcycling the commodity Researchers ...
- Here’s What We Believe About Pregnancy Beautyon July 12, 2022 at 6:00 am
A breakdown of how Romper selected winners for our Pregnancy Beauty Awards, including the ingredients we avoided, methodology, and science.
- Nephropathic Cystinosis Treatment Market Outlook, Trend, Growth and Share Estimation Analysison July 11, 2022 at 11:16 pm
This can be attributed to easy accessibility of symptomatic as well as cysteamine therapies at retail pharmacies and patient assistance programs by specialty pharmacies. Request for Analysis of ...
- The antiviral effects of thiol drugs in COVID-19on July 1, 2022 at 2:38 am
Potent inhibitory effects were noted with 2-mercaptoethane sulfonate sodium salt (Mesna), cysteamine, bucillamine, and WR-1065 (the active metabolite of the amifostine prodrug). The effectiveness ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Atherosclerosis no. 1 cause of death in Richmond area, heart attacks no. 3on July 29, 2022 at 3:00 am
Frances Givens, of Bon Air, began to feel dizzy while coming out of a department store. She didn’t pass or fall down. There were no headaches or chest ...
- AI-based heart health platform Cleerly raises $192Mon July 25, 2022 at 7:00 am
"We've measured indirect markers or surrogates of heart disease, like LDL cholesterol. Turns out there's an 80% overlap between cholesterol levels and patients who do versus do not have heart attacks.
- Study suggests a possible treatment approach for cancer and cardiovascular diseaseon July 25, 2022 at 3:44 am
A key molecule for cancer metastasis has been identified as a molecule already known for its involvement in cardiovascular disease, suggesting a possible treatment approach for both diseases ...
- Vascular Stent Market Latest Trends, Size, Key Players, Revenue and Forecast 2028on July 21, 2022 at 1:33 am
The Global Vascular Stent Market is forecasted to register a CAGR of over 7.6% during the forecast period 2022 to ...
- Higher cardiovascular health may partially offset increased genetic risk for strokeon July 20, 2022 at 2:00 am
The researchers reviewed data from the Atherosclerosis Risk in Communities Study, a 28-year study of 11,568 white and Black men and women, to create a polygenic risk score, or genetic map of stroke ...